Market First Transit Scientific offers the XO Score and XO Cross portfolio as FDA and CE cleared peripheral devices, presenting an opportunity to target vascular interventional centers looking to expand their device offerings with minimally invasive scoring and microcatheter solutions.

Product Expansion The company has a history of launching multiple microcatheters and scoring sheaths across 2Fr to 3.8Fr sizes, suggesting potential for expansion into new vessel applications or lengths to address challenging lesions and complex anatomy.

Clinical Adoption Recent clinical introductions and multi-site deployments indicate growing user familiarity; focus sales efforts on centers with complex lesion profiles and a track record of adopting advanced catheter tech to drive adoption of XO Score and XO Cross tools.

Awards and Validation Recognition from Medical Design Excellence Awards and ongoing regulatory clearance support can be leveraged to build credibility with procurement and KOLs, opening conversations around case studies, reimbursement pathways, and center certifications.

Strategic Partnerships With a lean team and a patent-rich technology stack, there is potential to pursue collaborations with larger distributors or hospital networks to scale reach, especially given the global expansion plans outlined for Europe and other regions.